Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer.
about
Antacid Use and De Novo Brain Metastases in Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Were Treated Using First-Line First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorsExposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.Efficacy of tyrosine kinase inhibitors in non-small-cell lung cancer patients undergoing dose reduction and those with a low body surface areaErlotinib augmentation with dapsone for rash mitigation and increased anti-cancer effectivenessEfficacy of first-line erlotinib in non-small cell lung cancer patients undergoing dose reduction and those with a low body surface area: A population-based observational study by the Ibaraki Thoracic Integrative (POSITIVE) Research GroupEGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction.Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics.Intestinal and hepatic drug transporters: pharmacokinetic, pathophysiological, and pharmacogenetic roles.Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature.Oral Targeted Therapies and Central Nervous System (CNS) Metastases.Targeted cancer therapy: interactions with other medicines.The strange connection between epidermal growth factor receptor tyrosine kinase inhibitors and dapsone: from rash mitigation to the increase in anti-tumor activity.Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma.Pulsed Erlotinib as Sole Treatment of Leptomeningeal Carcinomatosis: Can We Avoid the Use of Intrathecal Therapy?Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study.Associations between ABCG2 gene polymorphisms and gefitinib toxicity in non-small cell lung cancer: a meta-analysis.Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience.Population pharmacokinetics of erlotinib in Japanese patients with advanced non-small cell lung cancer.Comparison of the pharmacokinetics of erlotinib administered in complete fasting and 2 h after a meal in patients with lung cancer.Association of axitinib plasma exposure and genetic polymorphisms of ABC transporters with axitinib-induced toxicities in patients with renal cell carcinoma.Erlotinib treatment of meningeal carcinomatosis in lung cancer: more is better.
P2860
Q28550276-B7BEB485-5A82-4EC5-9E20-08BA290FBD8FQ33411001-B2892A11-83F9-4EC8-A218-801118EE02A5Q33418378-C2134B91-2771-4B57-8400-AE121B5C62CBQ33733770-4879766A-A4F5-4F9E-BC09-6C940ED9856EQ36234132-2252212F-D4F7-4B3E-B3CB-B63F9BCD6824Q36640486-12B1B321-ADEB-4D83-A3F7-79A7BA3D6FDEQ37709182-8BC137E6-E520-4A32-8C78-0E8856E5949CQ38207943-FCF885EC-49A8-4F9D-BBE0-3A7A0258A4C8Q38379295-98CD1CB9-F23C-4090-AFA5-C53F8A3E9D80Q38414396-BABC690B-A26E-4AD0-9FFD-D7424EC8550DQ38631975-D0AB49FA-7D28-4E39-8895-F285618C01BAQ38817201-45D34D9A-6EF0-40BF-9484-2B4BAC010838Q38891976-1F5A809F-C7B1-4560-A44E-EAF35C16EB3BQ40698804-6023CAC7-0514-4E06-9301-12D6D20E9668Q44434925-41A9E866-9F3C-43EA-B79B-92332A3A34F8Q47637910-8DA9700C-EBDA-4499-B0FF-FB798ED6C49EQ49236521-1ADF26E6-A917-4FB8-A286-452C74A3F55BQ50246515-1EA787F4-6897-4280-A449-571B10DBC602Q51011218-540C0C9D-631B-4396-81A1-938DC5CCA199Q51302682-AB2E220C-CEA9-4B55-8B72-33721BF88B11Q51537517-42121CD1-FF27-40B1-96B0-A1D1EC904799Q54335384-831DAF1D-3BC6-418D-9AE7-D52B88F5FB05
P2860
Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Population pharmacokinetics/ph ...... th non-small cell lung cancer.
@en
Population pharmacokinetics/ph ...... th non-small cell lung cancer.
@nl
type
label
Population pharmacokinetics/ph ...... th non-small cell lung cancer.
@en
Population pharmacokinetics/ph ...... th non-small cell lung cancer.
@nl
prefLabel
Population pharmacokinetics/ph ...... th non-small cell lung cancer.
@en
Population pharmacokinetics/ph ...... th non-small cell lung cancer.
@nl
P2093
P2860
P1476
Population pharmacokinetics/ph ...... th non-small cell lung cancer.
@en
P2093
Katsuhiro Masago
Ken-Ichi Inui
Masahide Fukudo
Michiaki Mishima
Satoshi Teramukai
Tadashi Mio
Tomohiro Terada
Toshiya Katsura
Yasuaki Ikemi
Yosuke Togashi
P2860
P2888
P304
P356
10.1007/S40262-013-0058-5
P577
2013-07-01T00:00:00Z
P5875
P6179
1014765401